Snowden Capital Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History

Snowden Capital Advisors’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,668	Closed	-$217K	–	1298
2025 Q4	$217K	Sell	4,668 -209	-4%	-$9.3K	0.01%	1183
2025 Q3	$203K	Buy	+4,877	New	+$156K	0.01%	1195
2025 Q1	–	Sell	-5,182	Closed	-$265K	–	1213
2024 Q4	$265K	Buy	5,182 +39	+0.8%	+$2.18K	0.01%	1045
2024 Q3	$263K	Buy	5,143 +109	+2%	+$5.62K	0.01%	1066
2024 Q2	$225K	Sell	5,034 -101	-2%	-$4.66K	0.01%	1093
2024 Q1	$240K	Buy	+5,135	New	+$201K	0.01%	1059

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Snowden Capital Advisors's CRNX Position: Q1 2026 in Review

Snowden Capital Advisors sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2026, closing a stake of 4,668 shares — an estimated $217K sold.

Snowden Capital Advisors first reported a position in CRNX in Q1 2024 and held it in 6 quarters. The position peaked at $265K in Q4 2024. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

Snowden Capital Advisors reported no remaining Crinetics Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Snowden Capital Advisors sold 4,668 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $217K.
Snowden Capital Advisors first reported a position in Crinetics Pharmaceuticals in Q1 2024 and held it in 6 quarters.
Snowden Capital Advisors's Crinetics Pharmaceuticals position peaked at $265K in Q4 2024.
243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Snowden Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.